# Nvidia-Backed Iambic Therapeutics Prices IPO at $16 a Share By John Kim Canonical URL: https://www.tokenpost.com/news/business/32145 Published: 2026-10-15T00:42:20.000Z Updated: 2026-10-15T00:42:20.000Z Section: Business > The AI drug developer is offering about 9.38 million shares and expects to begin trading on Nasdaq on Oct. 15 under ticker IAM. A $16 IPO price puts Nvidia-backed Iambic Therapeutics on track to begin Nasdaq trading Oct. 15, with the offering implying a market value of about $758 million for the AI drug developer. Iambic is offering about 9.38 million shares at the midpoint of a $15-to-$17 price range and plans to raise $150 million. The implied valuation is below the more than $800 million figure in [Iambic's earlier Nasdaq plan](). The fundraising is intended to advance three early-stage cancer drug candidates. ARK and a family office affiliated with Druckenmiller had expressed interest in subscribing for up to $60 million in shares combined. Iambic expects its shares to begin trading on Nasdaq on Oct. 15 under the ticker IAM. ## Links in this article - [Iambic's earlier Nasdaq plan](https://www.tokenpost.com/news/business/28101)